Clinical Trial Update: Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for humoral immunodeficiency treated with rituximab and subcutaneous immunoglobulin in Phase 2 and Phase 3; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency

Drugs mentioned

• Rituximab (rituximab)
• Subcutaneous immunoglobulin (immunoglobulin)

Snippet

Sponsor: Rochester General Hospital | Conditions: Secondary Immune Deficiency | Phase 2, Phase 3 | Status: COMPLETED